This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

19 Jul 2011

OncoVista Starts Additional Safety Study of Cancer Drug

OncoVista Innovative Therapies, Inc. reported that it has initiated an additional safety study of OVI-117 in a 2nd animal species.

Biopharmaceutical company OncoVista Innovative Therapies has initiated an additional safety study of cancer drug OVI-117 in a second animal species.


The drug is used for the treatment of solid tumours, such as breast, colon and prostate cancers, and targets thymidylate synthase.


OncoVista Innovative Therapies CEO Alexander Weis said that the additional safety study of OVI-117 is an important step in efforts to bring the drug candidate into clinical trials.


The company is completing the GLP animal toxicology studies and preparing the IND submission to the US FDA, and expects to launch a Phase I trial in the fourth quarter of 2011.

Related News